Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Catalyst Grant: Ethics

McMaster University

$93,793.00

Ethical Considerations for Health Technology Policy About Non-Invasive Prenatal Testing via Fetal DNA in Maternal Blood

EF 2013-14

Résumé
Non-Invasive Prenatal Testing (NIPT) is a new type of test that can identify genetic conditions in a fetus as early as the 8th week of pregnancy. It does this by analyzing small amounts of fetal DNA found in the mother's blood. It is different from existing forms of prenatal testing because 1) it can give very accurate results very early in pregnancy; 2) there is no risk of miscarriage or harm to the fetus; 3) there is the potential to identify many different types of genetic conditions. This project examines the ethical implications of this new test, with the intention of informing health policy about this new technology. This project also develops methods for incorporating ethical analysis into health technology policy, testing and refining an existing framework.
Programme
Catalyst Grant: Ethics
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
305382
Name
Vanstone Meredith
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Catalyst Grant : Ethics (2016-2017)
Projecttitle
Ethical Considerations for Health Technology Policy About Non-Invasive Prenatal Testing via Fetal DNA in Maternal Blood
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$93,793
Cihrequipment2
$0
Programname2
Catalyst Grant: Ethics
Keyworddelim
Constructivist Grounded Theory; Direct-To-Consumer Marketing; Empirical Ethics; Health Policy; Health Technology Assessment; Non-Invasive Prenatal Testing; Prenatal Testing; Qualitative Research; Relational Autonomy
Abstract
Non-Invasive Prenatal Testing (NIPT) is a new type of test that can identify genetic conditions in a fetus as early as the 8th week of pregnancy. It does this by analyzing small amounts of fetal DNA found in the mother's blood. It is different from existing forms of prenatal testing because 1) it can give very accurate results very early in pregnancy; 2) there is no risk of miscarriage or harm to the fetus; 3) there is the potential to identify many different types of genetic conditions. This project examines the ethical implications of this new test, with the intention of informing health policy about this new technology. This project also develops methods for incorporating ethical analysis into health technology policy, testing and refining an existing framework.
Competitiondate
201403
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Vanstone, Meredith
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $93,793~ $0~